Apogee Therapeutics Inc

APGE has broken above a Bullish Pivot Point following the 9-/20-day EMAs crossing above the 50-day SMA, signaling structural repair and a shift toward upward mean reversion in a Stage 2 context. Medium-term bias remains bullish, supported by rising intermediate moving averages and a sequence of higher highs and lows. Short-term execution is favorable, with price holding just above the 9-/20-day EMA zone after a sharp spike. Participation aligns with the speculative strategy’s requirement for visible asymmetry, focusing on reclaim and acceptance around the short-term EMAs.

• ↑AbbVie acquisition at $135.11/share to close Q3 2026 offers a ~premium to market
• ↑Phase 2 APEX trial showed 65.9% mid-dose patients hitting EASI-75 vs placebo
• ↓Q2 2026 net loss of $85.9 M and $67.3 M R&D spend strain margins